As the LDLR has previously been demonstrated to be important for hypercholesterolemia-associated breast cancer growth in preclinical models, future studies should explore if targeting MAPK, RSK signaling or ZFP36L1 activity in TNBC provides an additive benefit in the setting of hypercholesterolemia. Here, RPS6KA2 is linked to breast cancer.